Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Vaccinex Inc (VCNX)

Vaccinex Inc (VCNX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 2,756
  • Shares Outstanding, K 2,600
  • Annual Sales, $ 570 K
  • Annual Income, $ -20,250 K
  • EBIT $ -20 M
  • EBITDA $ -20 M
  • 60-Month Beta 1.10
  • Price/Sales 6.43
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -47.72
  • Most Recent Earnings $-2.28 on 11/14/24
  • Next Earnings Date 04/01/25
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.3100 +125.81%
on 11/26/25
0.7000 unch
on 12/18/25
+0.0383 (+5.79%)
since 11/17/25
3-Month
0.3100 +125.81%
on 11/26/25
1.1300 -38.05%
on 10/02/25
unch (unch)
since 09/18/25

Most Recent Stories

More News
Vaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer at ASCO Annual Meeting

VCNX : 0.7000 (+17.04%)
Vaccinex to Report Promising New Clinical Data Revealing Pepinemab’s Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research (AACR)

VCNX : 0.7000 (+17.04%)
Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market

VCNX : 0.7000 (+17.04%)
Vaccinex, Inc. Faces Delisting from Nasdaq Due to Failure to Meet Continued Listing Standards

Vaccinex announces Nasdaq delisting due to non-compliance with equity standards; trading shifts to OTC Markets.Quiver AI SummaryVaccinex, Inc., a clinical-stage biotechnology company focused on treating...

VCNX : 0.7000 (+17.04%)
Vaccinex, Inc. Reports Q3 Financial Results and Advances Alzheimer’s Development While Exploring Partnership Opportunities

Vaccinex reports promising Alzheimer’s treatment results, financial updates, and plans for partnerships to enhance development.Quiver AI SummaryVaccinex, Inc. has reported its financial results for the...

VCNX : 0.7000 (+17.04%)
Vaccinex Reports Third Quarter 2024 Financial Results and Provides Corporate Update

VCNX : 0.7000 (+17.04%)
Vaccinex Provides Update on ActivMAb® Platform: Multiple Project Deals and Presentation at SITC

VCNX : 0.7000 (+17.04%)
Vaccinex Reports Improved Immunity Correlating with Clinical Benefit of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer’s Annual Meeting

VCNX : 0.7000 (+17.04%)
Vaccinex Reports New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab at Clinical Trials on Alzheimer’s Disease (CTAD) Conference in Madrid, Spain

VCNX : 0.7000 (+17.04%)
Vaccinex to Report Promising New Efficacy Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab at Clinical Trials on Alzheimer’s Disease (CTAD) Conference on October 31, 2024

VCNX : 0.7000 (+17.04%)

Business Summary

Vaccinex, Inc. is a clinical-stage immunotherapy company. It engages in the discovery and development of biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases and autoimmune disorders. The company's product pipeline consists of...

See More

Key Turning Points

3rd Resistance Point 0.5981
2nd Resistance Point 0.5981
1st Resistance Point 0.5981
Last Price 0.7000
1st Support Level 0.5981
2nd Support Level 0.5981
3rd Support Level 0.5981

See More

52-Week High 1.4000
Fibonacci 61.8% 0.9615
Fibonacci 50% 0.8260
Last Price 0.7000
Fibonacci 38.2% 0.6906
52-Week Low 0.2521

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar